Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Expression of Potential Biomarker Targets by Immunohistochemistry in Cervical Carcinomas

Published:2022-01-24 Issue:6 Volume:41 Page:628-635
ISSN:0277-1691
Container-title:International Journal of Gynecological Pathology
language:en
Short-container-title:

Author:

Sun Lulu,Schroeder Molly C.,Hagemann Ian S.,Pfeifer John D.,Schwarz Julie K.,Grigsby Perry W.,Markovina Stephanie,Lin Alexander J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology,Pathology and Forensic Medicine

Reference42 articles.

1. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix;Dueñas-González;J Clin Oncol,2011

2. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial;Tangjitgamol;J Gynecol Oncol,2019

3. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials;Vale;J Clin Oncol,2008

4. Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: the randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274);Mileshkin;J Clin Oncol,2021

5. PD-1/PD-L1 inhibitors in cervical cancer;Liu;Front Pharmacol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of HER2 in Gastric-Type Endocervical Adenocarcinoma and its Prognostic Significance;Modern Pathology;2023-06

2. What is new in cancer-associated fibroblast biomarkers?;Cell Communication and Signaling;2023-05-04

3. The Role of Tumor-Associated Antigen HER2/neu in Tumor Development and the Different Approaches for Using It in Treatment: Many Choices and Future Directions;Cancers;2022-12-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3